Mediwound SEC Filings

MediWound Ltd. reported 2025 revenue of $16.96M, down from $20.22M in 2024, while net loss narrowed to $23.88M from $30.22M. Gross profit improved modestly, but Adjusted EBITDA loss widened to $20.31M from $14.76M, reflecting higher operating spending.

For the fourth quarter, revenue fell to $1.87M from $5.84M, with net loss deepening to $7.18M. Cash and short-term bank deposits were $53.14M as of December 31, 2025, and shareholders’ equity increased to $43.63M.

The company highlighted two key growth drivers: its Phase III EscharEx VALUE trial, expected to reach interim assessment and enrollment completion by year-end, and an expanded, operational NexoBrid manufacturing facility, with regulatory approvals expected in 2026. Management reaffirmed 2026–2028 revenue guidance.

MediWound Ltd. reported the results of an extraordinary general meeting of shareholders. As of the January 16, 2026 record date, there were 12,815,094 ordinary shares outstanding and entitled to vote. Shareholders holding 3,844,528 ordinary shares, about 30% of the outstanding shares, were present in person or by proxy, satisfying the quorum requirements under the company’s Articles of Association and Israeli Companies Law.

The single proposal presented at the meeting was approved by the requisite majority under the Israeli Companies Law, excluding abstentions. The final vote count showed 3,490,863 votes in favor (90.9%), 350,902 votes against (9.1%), and 2,763 abstentions. The 6-K and its exhibits are incorporated by reference into MediWound’s existing Form S-8 and Form F-3 registration statements.

T. Rowe Price Associates, Inc. filed an amended Schedule 13G/A reporting its beneficial ownership of 554,498 shares of MediWound Ltd. common stock, representing 4.3% of the class as of the event date. The firm has sole voting power over 535,181 shares and sole dispositive power over 554,498 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MediWound. T. Rowe Price Associates also affirms that the filing should not be construed as an admission that it is the beneficial owner of these securities.

HOLD Alapkezelo Zrt., a Hungarian investment fund management company, filed an amended ownership report showing a significant stake in MediWound Ltd. common shares.

The firm is deemed to beneficially own 1,039,954 common shares, representing approximately 8.1% of MediWound’s outstanding common stock, based on 12,835,186 shares outstanding as of January 16, 2026. HOLD Alapkezelo Zrt. has sole voting and sole dispositive power over all of these shares and no shared voting or dispositive power.

The filer certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of MediWound, and are not held in connection with any control-related transaction.

MediWound Ltd. reported ownership by a Rosalind-affiliated group in a Schedule 13G/A. Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon together report beneficial ownership of 912,319 MediWound common shares, or 7% of the class, based on 12,835,186 shares outstanding as of January 16, 2026.

The filing explains that this figure includes 163,265 shares issuable upon exercise of warrants that are subject to a 9.99% ownership blocker. Excluding those blocked warrants, Rosalind Master Fund may be deemed to beneficially own 749,054 shares, or about 5.84% of the common stock. The group states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of MediWound.

MediWound Ltd. investor Yelin Lapidot group reports a 5.95% passive stake in the company’s ordinary shares. Amendment No. 1 to Schedule 13G shows Yelin Lapidot Holdings Management Ltd., together with Dov Yelin and Yair Lapidot, beneficially owning 763,069 ordinary shares with shared voting and dispositive power.

The stake is held through mutual and provident funds managed by wholly owned subsidiaries of Yelin Lapidot Holdings, for the benefit of fund members. The reporting persons expressly state the securities were not acquired and are not held to change or influence control of MediWound.

MediWound Ltd. has called an extraordinary general meeting for February 19, 2026 to ask shareholders to approve an increase of 300,000 ordinary shares reserved for issuance under its 2024 Share Incentive Plan. The record date for voting is the close of business on January 16, 2026, when 12,835,186 ordinary shares were issued and outstanding, with each share entitled to one vote.

The Board and compensation committee say the additional shares are needed to continue granting equity awards to employees, officers, directors and other service providers, since only about 132,996 unallocated shares remain available under the plan. If approved, the total equity incentive pool across the 2014 and 2024 plans would cover 1,724,819 shares on a fully diluted base of 16,826,464 shares, representing 10.25% potential dilution. The Board unanimously recommends voting “FOR” the proposal and plans to register the new 300,000-share pool on an additional Form S-8 after approval.

MediWound Ltd. filed a Form 6-K presenting a corporate update and multi‑year financial outlook ahead of the J.P. Morgan Healthcare Conference. The company reports approximately $17 million in 2025 revenue and now guides for $24–26 million in 2026, $32–35 million in 2027, and $50–55 million in 2028, supported by a $54 million cash position. Management notes that U.S. government shutdown–related delays affected fourth‑quarter revenue recognition but characterizes the impact as timing‑related.

The update highlights clinical and operational milestones. An interim assessment and enrollment completion for the Phase III EscharEx® VALUE trial in venous leg ulcers are expected by year‑end 2026, with planned expansion into diabetic foot and pressure ulcers during 2026. MediWound also reports that its expanded NexoBrid® manufacturing facility is fully operational, with regulatory approvals targeted for 2026. The revenue expectations and cash figures are described as preliminary, unaudited, and subject to change after year‑end 2025 audit procedures.

MediWound Ltd. submitted a Form 6-K to furnish a press release titled “MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update.” The filing notes that the full press release is attached as Exhibit 99.1 and contains the detailed financial and corporate information for the third quarter of 2025.

The company also states that the information in this Form 6-K, including Exhibit 99.1 but excluding quotes from senior management, is incorporated by reference into multiple existing registration statements on Form S-8 and Form F-3. This allows the attached information to be used in connection with those previously filed securities registration documents.

MediWound Ltd. (MDWD): Schedule 13D/A Amendment No. 6 filed by Access Industries affiliates, Clal entities, and Len Blavatnik updates ownership details. The group reports beneficial ownership of 1,481,521 Ordinary Shares, representing 11.56% of the class, based on 12,821,433 shares outstanding as of September 30, 2025.

Most reporting persons list shared voting and dispositive power over 1,481,521 shares. Clal Life Sciences L.P. directly owns 1,172,710 shares (9.15%) with sole voting and dispositive power. Clal Biotechnology Industries Ltd. directly owns 308,811 shares and may be deemed to share voting and investment power over the 1,172,710 shares held by Clal Life Sciences L.P. The amendment revises Items 5(a) and 5(b); the date of event is September 30, 2025.